With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success
Ever since its launch in 2020, RayzeBio has talked at length about building a platform company to fulfill the potential that radiopharmaceuticals hold — with seven active programs to boast. But it’s stayed mum about what those programs actually are, instead sticking to updates about new funding, hires or partnerships.
That’s by design, according to CEO Ken Song. The former Venrock VC and serial biotech entrepreneur wanted to make sure that he had a real business case before becoming more visible.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.